Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia

Tiffany K. Pon, Anjlee Mahajan, Aaron Rosenberg, Alpesh Amin, Digish Shah, Ian Jenkins, Vineet Gupta, Heather Hofmann, Anthony Bejjani, Richard H White

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Making a definitive diagnosis of heparin-induced thrombocytopenia (HIT) can be problematic. A prompt platelet rise following treatment has been proposed as a “post-test” criterion for diagnosis. However, the platelet response following discontinuation of heparin and initiation of a recommended alternative anticoagulant remains largely undefined and unstudied. This study aimed to characterize platelet response to initial treatment in patients with a low, intermediate, or high likelihood of having HIT. This was a multicenter retrospective cohort study. Patients were over 18 years in age, underwent serologic testing for HIT, and received alternative anticoagulation treatment for HIT. Classification of each patient’s likelihood of having HIT was based on an empiric, pre-hoc combination of the 4T score and serology results. The primary outcome for this study was a platelet count response after initiation of direct thrombin inhibitor (DTI) or fondaparinux therapy within 48 h. 124 patients were analyzed. The sensitivity and specificity of having an immediate platelet rise of at least 10,000/µL by day 2 after starting treatment among high-likelihood for HIT patients were 0.71 (95% CI 0.55–0.84) and 0.64 (95% CI 0.5–0.76), respectively. The negative predictive value of no platelet rise was 75.5% (95% CI 0.61–0.86). A prompt platelet count rise may be appropriate to consider along with other known criteria for the clinical diagnosis of HIT. The rise should be immediate following discontinuation of heparin and initiation of recommended treatment, with an upward rise within 48 h.

Original languageEnglish (US)
Pages (from-to)536-542
Number of pages7
JournalJournal of Thrombosis and Thrombolysis
Volume45
Issue number4
DOIs
StatePublished - May 1 2018

Fingerprint

Antithrombins
Thrombocytopenia
Heparin
Blood Platelets
Therapeutics
Platelet Count
fondaparinux
Serology
Anticoagulants
Cohort Studies
Retrospective Studies
Outcome Assessment (Health Care)
Sensitivity and Specificity

Keywords

  • Anticoagulants
  • Diagnosis
  • Heparin
  • Platelet count
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. / Pon, Tiffany K.; Mahajan, Anjlee; Rosenberg, Aaron; Amin, Alpesh; Shah, Digish; Jenkins, Ian; Gupta, Vineet; Hofmann, Heather; Bejjani, Anthony; White, Richard H.

In: Journal of Thrombosis and Thrombolysis, Vol. 45, No. 4, 01.05.2018, p. 536-542.

Research output: Contribution to journalArticle

Pon, Tiffany K. ; Mahajan, Anjlee ; Rosenberg, Aaron ; Amin, Alpesh ; Shah, Digish ; Jenkins, Ian ; Gupta, Vineet ; Hofmann, Heather ; Bejjani, Anthony ; White, Richard H. / Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. In: Journal of Thrombosis and Thrombolysis. 2018 ; Vol. 45, No. 4. pp. 536-542.
@article{156ce513d6ac406c97d5d41f7a17d87a,
title = "Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia",
abstract = "Making a definitive diagnosis of heparin-induced thrombocytopenia (HIT) can be problematic. A prompt platelet rise following treatment has been proposed as a “post-test” criterion for diagnosis. However, the platelet response following discontinuation of heparin and initiation of a recommended alternative anticoagulant remains largely undefined and unstudied. This study aimed to characterize platelet response to initial treatment in patients with a low, intermediate, or high likelihood of having HIT. This was a multicenter retrospective cohort study. Patients were over 18 years in age, underwent serologic testing for HIT, and received alternative anticoagulation treatment for HIT. Classification of each patient’s likelihood of having HIT was based on an empiric, pre-hoc combination of the 4T score and serology results. The primary outcome for this study was a platelet count response after initiation of direct thrombin inhibitor (DTI) or fondaparinux therapy within 48 h. 124 patients were analyzed. The sensitivity and specificity of having an immediate platelet rise of at least 10,000/µL by day 2 after starting treatment among high-likelihood for HIT patients were 0.71 (95{\%} CI 0.55–0.84) and 0.64 (95{\%} CI 0.5–0.76), respectively. The negative predictive value of no platelet rise was 75.5{\%} (95{\%} CI 0.61–0.86). A prompt platelet count rise may be appropriate to consider along with other known criteria for the clinical diagnosis of HIT. The rise should be immediate following discontinuation of heparin and initiation of recommended treatment, with an upward rise within 48 h.",
keywords = "Anticoagulants, Diagnosis, Heparin, Platelet count, Thrombocytopenia",
author = "Pon, {Tiffany K.} and Anjlee Mahajan and Aaron Rosenberg and Alpesh Amin and Digish Shah and Ian Jenkins and Vineet Gupta and Heather Hofmann and Anthony Bejjani and White, {Richard H}",
year = "2018",
month = "5",
day = "1",
doi = "10.1007/s11239-018-1646-x",
language = "English (US)",
volume = "45",
pages = "536--542",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia

AU - Pon, Tiffany K.

AU - Mahajan, Anjlee

AU - Rosenberg, Aaron

AU - Amin, Alpesh

AU - Shah, Digish

AU - Jenkins, Ian

AU - Gupta, Vineet

AU - Hofmann, Heather

AU - Bejjani, Anthony

AU - White, Richard H

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Making a definitive diagnosis of heparin-induced thrombocytopenia (HIT) can be problematic. A prompt platelet rise following treatment has been proposed as a “post-test” criterion for diagnosis. However, the platelet response following discontinuation of heparin and initiation of a recommended alternative anticoagulant remains largely undefined and unstudied. This study aimed to characterize platelet response to initial treatment in patients with a low, intermediate, or high likelihood of having HIT. This was a multicenter retrospective cohort study. Patients were over 18 years in age, underwent serologic testing for HIT, and received alternative anticoagulation treatment for HIT. Classification of each patient’s likelihood of having HIT was based on an empiric, pre-hoc combination of the 4T score and serology results. The primary outcome for this study was a platelet count response after initiation of direct thrombin inhibitor (DTI) or fondaparinux therapy within 48 h. 124 patients were analyzed. The sensitivity and specificity of having an immediate platelet rise of at least 10,000/µL by day 2 after starting treatment among high-likelihood for HIT patients were 0.71 (95% CI 0.55–0.84) and 0.64 (95% CI 0.5–0.76), respectively. The negative predictive value of no platelet rise was 75.5% (95% CI 0.61–0.86). A prompt platelet count rise may be appropriate to consider along with other known criteria for the clinical diagnosis of HIT. The rise should be immediate following discontinuation of heparin and initiation of recommended treatment, with an upward rise within 48 h.

AB - Making a definitive diagnosis of heparin-induced thrombocytopenia (HIT) can be problematic. A prompt platelet rise following treatment has been proposed as a “post-test” criterion for diagnosis. However, the platelet response following discontinuation of heparin and initiation of a recommended alternative anticoagulant remains largely undefined and unstudied. This study aimed to characterize platelet response to initial treatment in patients with a low, intermediate, or high likelihood of having HIT. This was a multicenter retrospective cohort study. Patients were over 18 years in age, underwent serologic testing for HIT, and received alternative anticoagulation treatment for HIT. Classification of each patient’s likelihood of having HIT was based on an empiric, pre-hoc combination of the 4T score and serology results. The primary outcome for this study was a platelet count response after initiation of direct thrombin inhibitor (DTI) or fondaparinux therapy within 48 h. 124 patients were analyzed. The sensitivity and specificity of having an immediate platelet rise of at least 10,000/µL by day 2 after starting treatment among high-likelihood for HIT patients were 0.71 (95% CI 0.55–0.84) and 0.64 (95% CI 0.5–0.76), respectively. The negative predictive value of no platelet rise was 75.5% (95% CI 0.61–0.86). A prompt platelet count rise may be appropriate to consider along with other known criteria for the clinical diagnosis of HIT. The rise should be immediate following discontinuation of heparin and initiation of recommended treatment, with an upward rise within 48 h.

KW - Anticoagulants

KW - Diagnosis

KW - Heparin

KW - Platelet count

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85044392834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044392834&partnerID=8YFLogxK

U2 - 10.1007/s11239-018-1646-x

DO - 10.1007/s11239-018-1646-x

M3 - Article

C2 - 29574610

AN - SCOPUS:85044392834

VL - 45

SP - 536

EP - 542

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 4

ER -